|
|||||
|
|
| Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830] | |
| 摘 要： | |
| 本文献已被 ScienceDirect 等数据库收录！ | |